Company / R&D Expense
Beam Therapeutics Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$409.6M
FY2025
5-year range
$311.6M / $437.4M
FY2021-FY2025
Trend
+11.4%
vs FY2024
Sector context
#43 of 210
Health Care
What the data says
Beam Therapeutics Inc.'s r&d expense of $410M is higher than 80% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 7 years, ranging from $55M in FY2020 to $437M in FY2023.
Based on SEC 10-K filings.
$410M in FY2025 with a 5-year CAGR of +49.6%. Top quartile in the Health Care sector.
Declined from $437M to $410M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.5%
- 5-Year CAGR
- +49.6%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 210This company $409.6M Sector average $644.1M
▼
-36.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +49.6%, indicating consistent growth.
- In FY2025, r&d expense increased 11.4% year-over-year.
- Ranks #43 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $409.6M | +11.4% |
| FY2024 | $367.6M | -16.0% |
| FY2023 | $437.4M | +40.4% |
| FY2022 | $311.6M | -19.5% |
| FY2021 | $387.1M | +608.7% |
| FY2020 | $54.6M | +0.0% |
| FY2019 | $54.6M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026